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introduction
Fragility fractures in elderly can be the long term
consequence of an increase in bone remodeling, leading to bone
loss with micro structural alterations of both cortical and
trabecular structures (1, 2). in the primary prevention of
osteoporosis, adequate nutrition and physical activity are
important determinants of bone health throughout life. in the
secondary prevention, several pharmaceutical agents have been
shown to substantially reduce the risk of incident fragility
fractures in postmenopausal women and in elderly (3-6).
secondary prevention of osteoporosis, however, cannot merely
be limited to drug prescription. the adequate response to
pharmaceutical treatment for preventing both further
deterioration of bone structure and reducing the risk of falling
is dependent upon other accompanying measures, among which
nutrition is an essential contributor (7). Vitamin D, whenever
cutaneous sources do not meet the needs, calcium and proteins
are three nutrients influencing key processes in the acquisition
and maintenance of bone structure. several reviews on vitamin
D, calcium (8-14) and proteins intakes (15-21) have
underscored the importance of these three nutrients in the
prevention of bone loss and, thereby in reducing the risk of
fragility fracture in elderly. 
Dairy products, by providing both calcium and proteins, can
be expected to play a positive role on bone health. Milk
consumption has been shown to favorably affect bone
remodeling in postmenopausal women (22, 23) and in elderly
(24). in an open study carried out in institutionalized vitamin D
deficient women, we observed an apparent beneficial effect on
bone turnover markers after  4 weeks of soft plain cheese
consumption, providing about 17-25 % of the recommended
daily intakes of vitamin D, calcium and proteins (25). 
in the present report, we investigated, in another cohort of
institutionalized elderly women, and using a crossover
controlled study design whether the same intervention could
significantly reduce bone resorption markers. in order to
optimally capture any change in bone resorption rate, two
circulating markers of this process were monitored atthe end of
two sequential 6-week periods, with and without soft plain
cheese consumption. one biochemical marker (ctX) was
selected for its capacity to reflect more change in osteoclast
function, whereas the other (traP 5b) would preferentially
capture modification in the number of osteoclast (26). as
designed the present study could also adequately assess how
well the tested food was tolerated.    
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abstract: Background: nutritional approach to the deterioration of bone integrity and increased fracture risk
appears to be particularly appropriate in elderly women living in nursing homes. Objective: to investigate the
beneficial effect of the consumption of soft plain cheese on bone resorption markers in institutionalized elderly
women. Design: Prospective, randomized crossover controlled study. Setting: six French nursing homes or other
institutions for elderly. Participants: institutionalized women ≥ 65 years old with low vitamin D status and
calcium intake below 700 mg/day. Intervention: consumption of soft plain cheese made of semi-skimmed milk
which was fortified by both vitamin D3 (+1.25µg/100g) and milk extracted ca, thus achieving a total ca content
of 151 mg/100g as compared to about 118 mg/100g for standard fresh cheese. two servings were taken every
day during the 6 weeks that preceded or followed a period of 6 weeks without soft plain cheese consumption.
Measurements: the primary end point was the change in serum carboxy terminal cross-linked telopeptide of type
i collagen (ctX) selected as a marker of bone resorption. Results: 29 women aged 73-94 yr were selected, 21 of
them with mean age 87.2±6.1 years remained compliant. the intervention increased calcium and protein intakes
by 51% (904±228 vs. 599±122 mg/d) and 33 % (74.2±17.1 vs. 55.6±12.7 g/d, mean±sD), respectively. the
dietary intervention was associated with a statistically significant increase in serum levels of both 25ohD and
iGF-i, while those of Pth, ctX and traP5b were significantly reduced. compliance was 93,4 %. the daily
consumption of two servings of soft plain cheese was well accepted in terms of tastiness and appetite suited
portion size. Conclusion: this randomized crossover controlled trial demonstrates  that in elderly women living
in nursing homes, the consumption of soft plain cheese increasing the supply of vitamin D, calcium and proteins,
could reduce bone resorption and thereby reduce the risk of incidental fragility fractures in the long term.
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the study involved six French nursing homes or institutions
for elderly. all of them were selected because they provided
both medical supervision and adequate food consumption
monitoring. the screening of the subjects for eligibility started
on January 28 2008, after the study protocol had been approved
by both the regional (lyon) and national (“Direction Générale
de la santé) ethical committees. 
inclusion/exclusion criteria were as follow: women ≥ 65
years old living in nursing or elderly people home
(etablissement d’hébergement pour Personnes agées
Dépendantes) having given their informed consent; calcium
intake lower than 700 mg daily as assessed by frequency
questionnaire (27); daily sun exposure of uncovered arms
limited to less than 20 minutes; serum level of 25-
hydroxyvitamin D (25ohD) ≥ 4 ng/ml in order to avoid
enrolling subjects with severe vitamin D deficiency requiring
appropriate medical management; serum Pth ≥ 46 ng/l and ≤
150 ng/l; creatinine clearance, as calculated according to
cockroft formula, either normal or moderately reduced with
value ≥ 30ml/min; appreciating to eat dairy foods;  Mini
nutritional assessment (Mna) with score ≥ 21 (28); no
consumption during the last 6 months of food enriched
withvitamin D and/or calcium; no treatment for osteoporosis or
other bone diseases, including the following pharmaceutical
agents: calcitonin, bisphosphonates, raloxifene, teriparatide,
strontium ranelate; no disease with poor prognosis at short
term; no participation in a clinical trial during the last 3 months
preceding the entry into the study; no osteoporotic fracture
during the 12 months preceding the study; not confined to bed
or taking meals in her private room. 
according to these inclusion/exclusion criteria 29, out of the
40 screened subjects were eventually enrolled into the study.
subjects were selected from the results recorded at a first visit
that took place about 3 weeks before the beginning of the trial.
the intervention consisted in the consumption of soft plain
cheese made of semi-skimmed milk which was enriched by
both vitamin D (+1.25 µg/100g) and milk calcium, thus
achieving a total calcium content of 151 mg/100g, as compared
to about 118 mg /100g for standard fresh cheese according to
the French ciQual food database. two servings of 100g each
were taken every day during 6 weeks. they provided daily: 164
Kcal; 2.5 µg vitamin D; 302 mg calcium; 233 mg phosphorus
14.2 g proteins. subjects were randomly assigned to consume
the tested dairy product during the first or the second 6-week
period. During the 12-week intervention phase, two blood
samples were collected, i.e. by the end of the 6-week periods
with and without soft plain cheese consumption. 
the main endpoints were the differences in two serum
markers of bone resorption, carboxy terminal cross-linked
telopeptide of type i collagen (ctX) and tartrate resistant acid
phosphatase, isoform 5b (traP 5b) between the end of the
period with and without soft plain cheese consumption. 
Biochemical measurements
calcium was measured by colorimetry, sodium and
potassium by indirect potentiometry with the use of specific
electrodes, and creatinine by the Jaffe reaction (roche
Diagnostics, Meylan, France). serum parathyroid hormone
(Pth), osteocalcin, amino-terminal propeptide of type i
procollagen (PinP), and carboxy terminal cross-linked
telopeptide of type i collagen (ctX, cross-laps) were measured
by automated immunochemiluminescence on the elecsys
platform (roche Diagnostics, Meylan, France), as previously
described (29). For these 4-biochemical analyses, the within-
and between-run coefficient of variations (cV) were lower than
5%, whatever the concentration tested. the reference range of
these assays was established in a group of 59 premenopausal
healthy women aged 35-48 years. all of them had regular
menses associated with plasma Fsh concentration below 12
mu/l. they received a single dose of 100’000 iu of vitamin D3
one week before the blood sampling. the reference ranges were
10-46 pg/ml, 13-32 ng/ml, 19-50 ng/ml, and 700-3000 pmol/l
for Pth, osteocalcin, P1nP, and c-tX, respectively. Bone
alkaline phosphatase (BaP) was measured by automated
immunochemiluminescence on the access ii platform
(Beckman-coulter, chaska, Minesota, usa). BaP within-run
cV was 6.7 % at mean concentration of 13.2 µg/l and below
5% at concentration above 25 µg/l. the reference range
established in healthy premenopausal women was 4-15 µg/l. 
tartrate resistant acid phosphatase, isoform 5b (traP 5b), a
surrogate marker of osteoclast number (26), was determined by
immunoassay using a monoclonal antibody raised against
traP 5b purified from human osteoclasts, and recombinant
human traP as a reference standard (Bone traP® enzyme
assay kit, sBa sciences). intra and inter assay coefficient of
variation are lower than 4.8 and 5.2 %, respectively.
the serum level of 25-hydroxyvitamin D (25ohD) was
measured by ria (Diasorin, stillwater, Minesota, usa) as
previously reported (30). Vitamin D insufficiency was defined
as a serum level of 25ohD lower than 30 ng/ml (42). serum
iGF-i was measured by an immunoradiometric assay (iGF-i
ria-ct, schering-cis Bio, Gif sur Yvette, France) based on
the use of two monoclonal antibodies directed toward different
iGF i epitopes. in this method, bound iGF i is displaced from
iGFBPs by acidification. a large excess of iGF-ii is then added
to the acid-treated serum to prevent reassociation of iGF-i with
its carrier proteins when buffer is added. the analytical
properties of this assay was recently reported (29). the normal
range of serum iGF-i in women aged 36-85 years was 68-247
ng/ml. 
Statistical analysis
the statistical power was estimated from the expected
change in serum ctX that was a priori considered as the main
endpoint of the study. By using a crossover design, it was
expected that a difference would be detected in serum ctX
between periods with and without soft plain cheese
consumption by 20% with a power of 80% and a two-sided of
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0.05. twenty-nine subjects were eventually enrolled in order to
secure a greater power to the study. taking into account a
measured intra-individual coefficient of variation (cV) of 10%,
15 % difference in serum ctX required a sample of 20 subjects
in a crossover-designed -study. 
the results are expressed as mean ± standard deviation (sD).
Paired student’s t test was usedto assess differences between
the values measured by the end of the two 6-week periods with
and without soft plain cheese consumption, except osteocalcin
for which a Wilcoxon rank-sum test was applied because of the
skewed distribution of this variable. P values ≤ 0.05 were
considered as statistically significant. statistical analysis was
made using the software sas, version 8.02.
results
the baseline demographic and biochemical characteristics,
as assessed at the inclusion visit, are described in tables 1 and
2. 
table 1 
Baseline demographic characteristics of the 29 enrolled
women, as assessed at the inclusion visit 
age (years) 86.9 ± 6.3
age at menopause (years) 48.7 ± 4.2
standing height (cm) 154 ± 8
Body weight (kg) 68.5 ± 15.6
BMi (kg/m2) 29.0 ± 6.4
calcium intake (mg/d) 604 ± 132
Protein intake (g/d) 61.5 ± 12.3
Mna 25.8 ± 2.2
all values are means ± sD; BMi: Body Mass index. ; Mna: Minimum nutritional
assessment. 
out of the twenty-nine included subjects who fulfilled
enrollment criteria, three women withdrew before the onset of
the trial. in three others, blood was not collected in the fasting
state, whereas for two women the dairy product was not taken
during more than 4 days out of the 6 weeks defined in the study
design. therefore, the influence of the intervention was
analyzed in 21 out of the 29 subjects initially enrolled at the
inclusion visit. the anthropometric, nutritional and biochemical
mean values of those 21 women kept in the analysis were not
statistically different (data not shown) from the 29 selected
subjects presented in table 1 and 2. 
overall, 44.8 % of the enrolled women had already
experienced at least one fracture with skeletal sites including
wrist or forearm, spine and hip.
as compared to the reference ranges of serum biochemical
analytes, mean albumin, and 25(ohD) values of the 29
enrolled subjects were low, whereas that of Pth was elevated
(table 2). to this high serum level of Pth was associated an
increase in the bone markers, ctX and P1nP above the
reference range established in premenopausal women, as
assessed in the investigator laboratory (29). the intervention
increased calcium and protein intakes by 51% (904±228 vs.
599±122 mg/d) and 33 % (74.2±17.1 vs. 55.6±12.7 g/d,
mean±sD), respectively.
table 2 
serum biochemical characteristics  in the 29 enrolled women as
assessed at the inclusion visit 
reference values
calcium (mmol/l) 2.24 ± 0.07 2.20 - 2.60
inorganic Phosphate (mmol/l) 1.12 ± 0.12 0.85 -1.40
albumin (g/l) 31.8 ± 2.7 35 - 50
Prealbumin (g/l) 0.23 ± 0.037 0.10 - 0.40
creatinine (µmol/l) 83.9 ± 25.9 44 - 80
tsh (mui/l) 2.2 ± 1.4 0.4 - 4.4
25ohD (ng/ml) 8.8 ± 7.5 30 - 80
Pth (ng/l) 75.8 ± 24.2 10 - 46*
ctX (pmol/l) 4325 ± 1948 700 – 3000 *
traP 5b (ng/ml) 5.75 ± 1.50 2.40 - 6.85 # 
osteocalcin (ng/ml) 30.3 ± 13.0 13 - 32*
BaP (µg/ml) 13.6 ± 5.3 4 - 15*
P1nP (ng/ml) 79.9 ± 31.8 19 - 50*
iGF-i (ng/ml) 111.6 ± 32.4 68-247
tsh: thyroid-stimulating hormone; 25ohD: 25-hydroxyvitamin D; Pth: Parathyroid
hormone; ctX: carboxy terminal crosslinked telopeptide of type i collagen; traP 5b:
tartrate resistant acid phosphatase, isoform 5b; BaP: Bone alkaline Phosphatase; P1nP :
amino-terminal propeptide of type i procollagen; iGF-i: insulin-like Growth Factor-i; 
* reference range established in healthy premenopausal women aged 35-48 years; 
# reference range established in healthy premenopausal women aged 22-54 years.
the dietary intervention produced a statistically significant
increase in serum levels of both 25ohD and iGF-i, while those
of Pth, ctX and traP5b were significantly reduced (Figure
1). no significant differences were recorded between the
intervention and the control period for serum calcium,
phosphate, albumin, prealbumin, BaP and P1nP (data not
shown). serum creatinine, which was slightly above the
reference range corresponding to a clearance moderately
reduced, but ≥30 ml/min using cokroft formula. it was not
modified by the intervention. Mna scores were not
significantly different by the end of the 6-week period with
(26.1±2.3) and without (26.3±1.9, mean±sD) soft plain cheese
consumption. 
the median number of soft plain cheese servings consumed
during the 6 intervention weeks was 84.0 (itt population
n=29). the median of consumption duration was 44.0 days
(itt population n=29). the corresponding compliance was
94.8 %. the soft plain cheese acceptability, as evaluated by the
end of the 6 weeks consumption was satisfactory with median
score on a scale from 0 to 10 (best) for the following criteria: a)
tastiness (8.0), b) portion size suited to subjects’ appetite (8.5),
c) absence of progressing tiredness during the food testing
period (8.0).      
discussion
elderly residents of age care facilities are at risk of suffering
from inadequacies of nutrients such as vitamin D, calcium and
proteins. in institutionalized elderly, insufficient supply of these
three nutrients, in addition to the lack of sun exposure as far as
vitamin D is concerned, amplifies the risk of fractures by
increasing both bone loss rate and fall propensity (31-35). hip
fracture incidence is particularly elevated in nursing home
residents, as observed in several countries (36-38). We recently
reported results of an open trial exploring whether consumption
of vitamin D and calcium enriched soft plain cheese may
modify bone turnover in a way expected to attenuate the rate of
bone loss among institutionalized elderly women (25). the
results of this exploratory study suggested that fortified soft
plain cheese consumed during one month by elderly women
with vitamin D insufficiency can reduce bone resorption
markers, namely ctX and traP 5b, by positively influencing
ca and protein economy, as expressed by decreased Pth and
increased iGF-i, respectively (25). the foregoing randomized
cross-over controlled study confirms that dietary intervention
with the same fortified soft plain cheese during 6 weeks
significantly reduced bone resorption, as expressed by the
significant decrease of both specific biochemical markers, ctX
and traP 5b. as in the initial open study (25), these changes
in bone resorption markers were associated with significant
increase in serum levels of both 25ohD and iGF-i.
nevertheless, the decrease in serum Pth level was attenuated
as compared to the former open trial. of note, the new study
indicated the quite satisfactory adherence and tolerance by this
elderly women population of the soft plain cheese consumption,
as previously recorded in the open trial (25).   
in the former study, 43.2% (16 out of 37) of the enrolled
subjects with mean age (±sD) 84.8±8.1 years reported to have
experienced a fracture from the onset of menopause. in the
present study, the prevalence of fractures was quite similar
44.8% (13 out of 29). Both age and prior fracture are
recognized as two main clinical factors for the prediction of
fragility fracture risk (39). this underscores the high risk of
further fracture occurrence in institutionalized elderly women,
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figure 1
serum biochemical variables after 6 weeks without (empty circles) and with (hatched circles) soft white cheese consumption in 21
institutionalized women. Vertical bars are seM. P: statistical significance of the differences analyzed by paired t test. the
decrease in the two biochemical markers of bone resorption, ctX and traP 5b reflecting osteoclast function and number were
inhibited by 6.8% and 6% respectively, while osteocalcin was not decreased. see text for further details
out of which more than 40% have already experienced at least
one fracture. 
in bone-related diseases, particularly osteoporosis, changes
in clinical endpoints, such as bone mineral density and fragility
fractures, require months to years, respectively, to manifest.
therefore, bone biochemical markers are extremely useful to
predict the long-term responsiveness to treatment after a few
weeks. early changes in bone biochemical markers, particularly
those reflecting bone resorption, such as ctX, predict the long-
term rate of bone loss as well as the risk of incident fracture
(40-49). the magnitude of the reduction in markers of bone
resorption observed in the foregoing study is less than that
observed following therapeutic doses of strong inhibitors of
bone resorption such as bisphosphonates (44, 46, 47). But
reduction of lower magnitude was also observed with weaker
inhibitors of bone resorption, such as raloxifen (50), low doses
of estrogen (51) strontium ranelate (52) and calcium with
vitamin D supplementation (53). these compounds have been
shown to exert positive effects on bone health in elderly,
including reduction in vertebral fracture of similar magnitude to
that obtained with most powerful bisphosphonates. 
Much attention is now paid to scientific support for claims
on foods as they are related to the effects of dietary components
on body functions (54), including on bone health (55). in
calcium and vitamin D enriched foods, a reduction in
biochemical markers of bone resorption such as ctX and
traP5b in the present study, mimics the effect of
pharmaceutical supplementation combining this active
agents(53). the concomitant stimulation of iGF-i, after six
weeks of soft plain cheese consumption is similar to the early
rise recently reported with selective supplementation of milk
protein provided to elderly patients (56). Dietary proteins play a
key role in the production of iGF-i (15). this physiological
relation indicates that the function of proteins as supplied from
diet should not be considered as merely that of “brick supplier”
to the osteogenic cells, thus conferring on them the capacity to
lay down the organic bone matrix. amino acids from dietary
proteins stimulate the hepatic production of iGF-i and,
consequently, increase the circulating level of this growth
factor that exerts anabolic action on both bone forming and
skeletal muscle cells. the dietary protein-iGF-i system also
positively influences the calcium-phosphate economy, thus
favouring bone anabolism (18). Furthermore, some amino acids
can directly stimulate iGF-i production by osteoblastic cells
(57) or its expression in skeletal muscle cells (58). these
systemic and local actions of both iGF-i and amino acids
underscore the importance of adequate protein intake for
preventing bone loss and sarcopenia and thus, for reducing the
risk of fragility fractures in elderly (21). 
taken together, the biochemical changes observed in the
present study are compatible with the combined influence of
calcium, vitamin D and proteins, three nutrients contained in
the tested dairy product in an amount providing 17-25 % of the
daily recommended allowance for the elderly (59). 
in conclusion, this randomized cross-over controlled study
confirms a previous open trial by showing that, in elderly,
regular consumption of a dairy food supplying three nutrients
deemed to be essential for bone health exert a positive
influence on biochemical markers of bone metabolism.      
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